Claritas Pharmaceuticals, Inc.
CLAZF
$0.00
$0.000.00%
OTC PK
| 09/30/2021 | 06/30/2021 | 03/31/2021 | 12/31/2020 | 09/30/2020 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -22.62% | -19.98% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -133.76% | -112.71% | -- | -- | -- |
| Operating Income | 133.76% | 112.71% | -- | -- | -- |
| Income Before Tax | -194.21% | -208.45% | -- | -- | -- |
| Income Tax Expenses | -2,233.33% | -182.68% | -- | -- | -- |
| Earnings from Continuing Operations | -185.01% | -211.98% | -- | -- | -- |
| Earnings from Discontinued Operations | 91.88% | 85.43% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.33% | -26.99% | -- | -- | -- |
| EBIT | 133.76% | 112.71% | -- | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -25.67% | -19.41% | -- | -- | -- |
| Normalized Basic EPS | -1,172.00% | 22.17% | -- | -- | -- |
| EPS Diluted | -25.67% | -19.41% | -- | -- | -- |
| Normalized Diluted EPS | -1,172.00% | 22.17% | -- | -- | -- |
| Average Basic Shares Outstanding | 16.52% | 10.77% | -- | -- | -- |
| Average Diluted Shares Outstanding | 16.52% | 10.77% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |